IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 115, Issue 46, Pages E10915-E10924
Publisher
Proceedings of the National Academy of Sciences
Online
2018-10-30
DOI
10.1073/pnas.1811615115
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
- (2018) Rizwan Romee et al. BLOOD
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)
- (2018) Todd A. Fehniger et al. CANCER RESEARCH
- IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56 bright NK Cells and Increases NK-Cell Cytokine Release Capabilities
- (2017) Sigrid Dubois et al. Cancer Immunology Research
- CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
- (2016) Jae H. Park et al. BLOOD
- Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
- (2016) Rony Dahan et al. CANCER CELL
- Anti-PD-1 therapy in the frontline
- (2016) David Killock Nature Reviews Clinical Oncology
- Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
- (2015) David J. DiLillo et al. CELL
- The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
- (2015) M. Rosario et al. CLINICAL CANCER RESEARCH
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
- (2015) D. J. DiLillo et al. Cancer Immunology Research
- Rituximab: modes of action, remaining dispute and future perspective
- (2014) Abdulmunem Abulayha et al. Future Oncology
- Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action
- (2014) S. Dubois et al. JOURNAL OF IMMUNOLOGY
- Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse
- (2014) Marie Vincent et al. mAbs
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
- (2013) H. E. Kohrt et al. BLOOD
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Consequences of the crosstalk between monocytes/macrophages and natural killer cells
- (2013) Tatiana Michel et al. Frontiers in Immunology
- IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients
- (2012) María P. Roberti et al. BREAST CANCER RESEARCH AND TREATMENT
- Augmented IL-15R Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice
- (2012) M. Zhang et al. JOURNAL OF IMMUNOLOGY
- Macrophages Help NK Cells to Attack Tumor Cells by Stimulatory NKG2D Ligand but Protect Themselves from NK Killing by Inhibitory Ligand Qa-1
- (2012) Zhixia Zhou et al. PLoS One
- Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
- (2012) P. Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques
- (2011) T. A. Waldmann et al. BLOOD
- IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood
- (2011) M. C. Sneller et al. BLOOD
- Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression
- (2011) Esther Moga et al. EXPERIMENTAL HEMATOLOGY
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates
- (2010) E. Lugli et al. BLOOD
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- (2010) H. E. Kohrt et al. BLOOD
- Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
- (2010) P. Yu et al. CLINICAL CANCER RESEARCH
- Activating and inhibitory receptors of natural killer cells
- (2010) Hollie J Pegram et al. IMMUNOLOGY AND CELL BIOLOGY
- Fc RIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
- (2010) F. Nimmerjahn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma
- (2009) M Watanabe et al. BRITISH JOURNAL OF CANCER
- Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer
- (2009) M. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
- (2008) Jacob A. Klapper et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation